[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[S. 2195 Enrolled Bill (ENR)]
S.2195
One Hundred Eighth Congress
of the
United States of America
AT THE SECOND SESSION
Begun and held at the City of Washington on Tuesday,
the twentieth day of January, two thousand and four
An Act
To amend the Controlled Substances Act to clarify the definition of
anabolic steroids and to provide for research and education activities
relating to steroids and steroid precursors.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Anabolic Steroid Control Act of
2004''.
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.
(a) Definitions.--Section 102 of the Controlled Substances Act (21
U.S.C. 802) is amended--
(1) in paragraph (41)--
(A) by realigning the margin so as to align with paragraph
(40); and
(B) by striking subparagraph (A) and inserting the
following:
``(A) The term `anabolic steroid' means any drug or hormonal
substance, chemically and pharmacologically related to testosterone
(other than estrogens, progestins, corticosteroids, and
dehydroepiandrosterone), and includes--
``(i) androstanediol--
``(I) 3b,17b-dihydroxy-5a-androstane; and
``(II) 3a,17b-dihydroxy-5a-androstane;
``(ii) androstanedione (5a-androstan-3,17-dione);
``(iii) androstenediol--
``(I) 1-androstenediol (3b,17b-dihydroxy-5a-androst-1-ene);
``(II) 1-androstenediol (3a,17b-dihydroxy-5a-androst-1-
ene);
``(III) 4-androstenediol (3b,17b-dihydroxy-androst-4-ene);
and
``(IV) 5-androstenediol (3b,17b-dihydroxy-androst-5-ene);
``(iv) androstenedione--
``(I) 1-androstenedione ([5a]-androst-1-en-3,17-dione);
``(II) 4-androstenedione (androst-4-en-3,17-dione); and
``(III) 5-androstenedione (androst-5-en-3,17-dione);
``(v) bolasterone (7a,17a-dimethyl-17b-hydroxyandrost-4-en-3-
one);
``(vi) boldenone (17b-hydroxyandrost-1,4,-diene-3-one);
``(vii) calusterone (7b,17a-dimethyl-17b-hydroxyandrost-4-en-3-
one);
``(viii) clostebol (4-chloro-17b-hydroxyandrost-4-en-3-one);
``(ix) dehydrochloromethyltestosterone (4-chloro-17b-hydroxy-
17a-methyl-androst-1,4-dien-3-one);
``(x) <triangle>1-dihydrotestosterone (a.k.a. `1-testosterone')
(17b-hydroxy-5a-androst-1-en-3-one);
``(xi) 4-dihydrotestosterone (17b-hydroxy-androstan-3-one);
``(xii) drostanolone (17b-hydroxy-2a-methyl-5a-androstan-3-
one);
``(xiii) ethylestrenol (17a-ethyl-17b-hydroxyestr-4-ene);
``(xiv) fluoxymesterone (9-fluoro-17a-methyl-11b,17b-
dihydroxyandrost-4-en-3-one);
``(xv) formebolone (2-formyl-17a-methyl-11a,17b-
dihydroxyandrost-1,4-dien-3-one);
``(xvi) furazabol (17a-methyl-17b-hydroxyandrostano[2,3-c]-
furazan);
``(xvii) 13b-ethyl-17a-hydroxygon-4-en-3-one;
``(xviii) 4-hydroxytestosterone (4,17b-dihydroxy-androst-4-en-
3-one);
``(xix) 4-hydroxy-19-nortestosterone (4,17b-dihydroxy-estr-4-
en-3-one);
``(xx) mestanolone (17a-methyl-17b-hydroxy-5a-androstan-3-one);
``(xxi) mesterolone (1a-methyl-17b-hydroxy-[5a]-androstan-3-
one);
``(xxii) methandienone (17a-methyl-17b-hydroxyandrost-1,4-dien-
3-one);
``(xxiii) methandriol (17a-methyl-3b,17b-dihydroxyandrost-5-
ene);
``(xxiv) methenolone (1-methyl-17b-hydroxy-5a-androst-1-en-3-
one);
``(xxv) 17a-methyl-3b, 17b-dihydroxy-5a-androstane;
``(xxvi) 17a-methyl-3a,17b-dihydroxy-5a-androstane;
``(xxvii) 17a-methyl-3b,17b-dihydroxyandrost-4-ene.
``(xxviii) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-
hydroxy-17b-hydroxyestr-4-en-3-one);
``(xxix) methyldienolone (17a-methyl-17b-hydroxyestra-4,9(10)-
dien-3-one);
``(xxx) methyltrienolone (17a-methyl-17b-hydroxyestra-4,9-11-
trien-3-one);
``(xxxi) methyltestosterone (17a-methyl-17b-hydroxyandrost-4-
en-3-one);
``(xxxii) mibolerone (7a,17a-dimethyl-17b-hydroxyestr-4-en-3-
one);
``(xxxiii) 17a-methyl-<triangle>1-dihydrotestosterone (17b-
hydroxy-17a-methyl-5a-androst-1-en-3-one) (a.k.a. `17-a-methyl-1-
testosterone');
``(xxxiv) nandrolone (17b-hydroxyestr-4-en-3-one);
``(xxxv) norandrostenediol--
``(I) 19-nor-4-androstenediol (3b, 17b-dihydroxyestr-4-
ene);
``(II) 19-nor-4-androstenediol (3a, 17b-dihydroxyestr-4-
ene);
``(III) 19-nor-5-androstenediol (3b, 17b-dihydroxyestr-5-
ene); and
``(IV) 19-nor-5-androstenediol (3a, 17b-dihydroxyestr-5-
ene);
``(xxxvi) norandrostenedione--
``(I) 19-nor-4-androstenedione (estr-4-en-3,17-dione); and
``(II) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
``(xxxvii) norbolethone (13b,17a-diethyl-17b-hydroxygon-4-en-3-
one);
``(xxxviii) norclostebol (4-chloro-17b-hydroxyestr-4-en-3-one);
``(xxxix) norethandrolone (17a-ethyl-17b-hydroxyestr-4-en-3-
one);
``(xl) normethandrolone (17a-methyl-17b-hydroxyestr-4-en-3-
one);
``(xli) oxandrolone (17a-methyl-17b-hydroxy-2-oxa-[5a]-
androstan-3-one);
``(xlii) oxymesterone (17a-methyl-4,17b-dihydroxyandrost-4-en-
3-one);
``(xliii) oxymetholone (17a-methyl-2-hydroxymethylene-17b-
hydroxy-[5a]-androstan-3-one);
``(xliv) stanozolol (17a-methyl-17a-hydroxy-[5a]-androst-2-
eno[3,2-c]-pyrazole);
``(xlv) stenbolone (17b-hydroxy-2-methyl-[5a]-androst-1-en-3-
one);
``(xlvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-
dien-17-oic acid lactone);
``(xlvii) testosterone (17b-hydroxyandrost-4-en-3-one);
``(xlviii) tetrahydrogestrinone (13b,17a-diethyl-17b-
hydroxygon-4,9,11-trien-3-one);
``(xlix) trenbolone (17b-hydroxyestr-4,9,11-trien-3-one); and
``(xlx) any salt, ester, or ether of a drug or substance
described in this paragraph.
The substances excluded under this subparagraph may at any time be
scheduled by the Attorney General in accordance with the authority and
requirements of subsections (a) through (c) of section 201.''; and
(2) in paragraph (44), by inserting ``anabolic steroids,''
after ``marihuana,''.
(b) Authority and Criteria for Classification.--Section 201(g) of
the Controlled Substances Act (21 U.S.C. 811(g)) is amended--
(1) in paragraph (1), by striking ``substance from a schedule
if such substance'' and inserting ``drug which contains a
controlled substance from the application of titles II and III of
the Comprehensive Drug Abuse Prevention and Control Act (21 U.S.C.
802 et seq.) if such drug''; and
(2) in paragraph (3), by adding at the end the following:
``(C) Upon the recommendation of the Secretary of Health and
Human Services, a compound, mixture, or preparation which contains
any anabolic steroid, which is intended for administration to a
human being or an animal, and which, because of its concentration,
preparation, formulation or delivery system, does not present any
significant potential for abuse.''.
(c) Anabolic Steroids Control Act.--Section 1903 of the Anabolic
Steroids Control Act of 1990 (Public Law 101-647) is amended--
(1) by striking subsection (a); and
(2) by redesignating subsections (b) and (c) as subsections (a)
and (b), respectively.
(d) Effective Date.--The amendments made by this section shall take
effect 90 days after the date of enactment of this Act.
SEC. 3. SENTENCING COMMISSION GUIDELINES.
The United States Sentencing Commission shall--
(1) review the Federal sentencing guidelines with respect to
offenses involving anabolic steroids;
(2) consider amending the Federal sentencing guidelines to
provide for increased penalties with respect to offenses involving
anabolic steroids in a manner that reflects the seriousness of such
offenses and the need to deter anabolic steroid trafficking and
use; and
(3) take such other action that the Commission considers
necessary to carry out this section.
SEC. 4. PREVENTION AND EDUCATION PROGRAMS.
(a) In General.--The Secretary of Health and Human Services
(referred to in this Act as the ``Secretary'') shall award grants to
public and nonprofit private entities to enable such entities to carry
out science-based education programs in elementary and secondary
schools to highlight the harmful effects of anabolic steroids.
(b) Eligibility.--
(1) Application.--To be eligible for grants under subsection
(a), an entity shall prepare and submit to the Secretary an
application at such time, in such manner, and containing such
information as the Secretary may require.
(2) Preference.--In awarding grants under subsection (a), the
Secretary shall give preference to applicants that intend to use
grant funds to carry out programs based on--
(A) the Athletes Training and Learning to Avoid Steroids
program;
(B) The Athletes Targeting Healthy Exercise and Nutrition
Alternatives program; and
(C) other programs determined to be effective by the
National Institute on Drug Abuse.
(c) Use of Funds.--Amounts received under a grant under subsection
(a) shall be used for education programs that will directly communicate
with teachers, principals, coaches, as well as elementary and secondary
school children concerning the harmful effects of anabolic steroids.
(d) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section, $15,000,000 for each of fiscal
years 2005 through 2010.
SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.
(a) In General.--The Secretary of Health and Human Services shall
ensure that the National Survey on Drug Use and Health includes
questions concerning the use of anabolic steroids.
(b) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section, $1,000,000 for each of fiscal
years 2005 through 2010.
Speaker of the House of Representatives.
Vice President of the United States and
President of the Senate.